Date:
Wed, 05 Aug 2026 13:33:06 EDT
Content:
The U.S. Food and Drug Administration (FDA) has published a regulatory update regarding SNJ Labs Private Ltd., a pharmaceutical manufacturer located in Rajkot, Gujarat, India. This notice follows the agency’s assessment of the facility’s compliance with international safety and quality standards.
The documentation, which stems from inspections conducted earlier in 2026, highlights the FDA’s ongoing efforts to monitor overseas manufacturing sites. As a supplier of pharmaceutical components, SNJ Labs Private Ltd. is required to maintain strict adherence to Current Good Manufacturing Practice (CGMP) to ensure the safety and efficacy of products entering the U.S. market.
The FDA provides these updates to maintain transparency regarding the regulatory status of global drug manufacturers. Companies cited in such reports are expected to implement corrective actions to address any identified deficiencies and to prevent potential risks to public health.
Source: U.S. Food and Drug Administration
Link:
http://www.fda.gov/about-fda/snj-labs-private-ltd
Keywords:
FDA, SNJ Labs Private Ltd, India, Pharmaceutical Manufacturing, Regulatory Compliance, CGMP